| 내 용 |
Three years <a href=" https://marcusjoshuarecruitment.co.uk/purenudism-kids-2ff3.pdf ">new sexy</a> Patients in the earlier two-year Phase III studies who hadbeen in the control groups that received either a placebo orCopaxone - the current MS market leader from Teva PharmaceuticalIndustries - were given Tecfidera in the Enforceextension trial. They had similar favorable clinical responsesas those who had received the Biogen drug in the earlier trials,the company said.
|
